title: Failure of omalizumab for treatment of severe adult atopic dermatitis.
abstract: Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.
authors: Department of Dermatology, Baylor College of Medicine, Houston, Texas 77030, USA.
authors: Richard A
authors: RA
authors: Krathen
authors: Sylvia
authors: S
authors: Hsu
mesh_terms: D000328:Adult; D000367:Age Factors; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D012720:Severity of Illness Index; D017211:Treatment Failure
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab